Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
17.11
+0.35 (2.09%)
At close: Oct 2, 2026, 4:00 PM EDT
17.08
-0.03 (-0.18%)
After-hours: Oct 2, 2026, 4:10 PM EDT
Rallybio Revenue
Rallybio had revenue of $646.00K in the twelve months ending June 30, 2026, down -15.11% year-over-year. In the year 2025, Rallybio had annual revenue of $858.00K with 34.91% growth.
Revenue (ttm)
$646.00K
Revenue Growth
-15.11%
P/S Ratio
140.41
Revenue / Employee
$92,286
Employees
7
Market Cap
90.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 858.00K | 222.00K | 34.91% |
| Dec 31, 2024 | 636.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ImmuCell | 30.68M |
| Atara Biotherapeutics | 6.19M |
| NeurAxis | 5.32M |
| Nutriband | 1.62M |
| MediciNova | 920.48K |
| Cardiff Oncology | 508.00K |
| Fractyl Health | 3.00K |
RLYB News
- 1 month ago - Rallybio Quarterly report: Q2 2026 - Filings
- 4 months ago - Rallybio to acquire Avenzo Therapeutics through merger transaction - TheFly
- 4 months ago - Rallybio Transcript: M&A announcement - Transcripts
- 4 months ago - Rallybio Press release: M&A announcement - Filings
- 4 months ago - Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement - Business Wire
- 4 months ago - Rallybio Quarterly report: Q1 2026 - Filings
- 6 months ago - Rallybio Annual report: Q4 2025 - Filings
- 7 months ago - Rallybio, Candid Therapeutics announce merger agreement - TheFly